STOCK TITAN

Seven Fleet Files Schedule 13D After $50M Purchase of CG Oncology Stock

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

Seven Fleet filed a Schedule 13D disclosing an open-market purchase of CG Oncology common stock. Seven Fleet Partners purchased 1,540,819 shares for approximately $49,999,983, including a tranche of 1,515,151 shares bought on September 11, 2025 at $33.00 per share under the issuer's at-the-market offering. The filing reports beneficial ownership of 1,515,151 shares (1.9%) by the reporting entities based on 77,762,732 shares outstanding; Dr. Brian Liu is shown with shared voting power and direct holdings equating to 2%. The Reporting Persons state they view the shares as undervalued and may buy or sell, engage with management, or consider other strategic actions.

Positive

  • Significant capital commitment: Seven Fleet Partners purchased 1,540,819 shares for approximately $49,999,983 indicating material investor interest.
  • Transparent intent: Schedule 13D discloses potential engagement with management and flexibility to increase position or discuss strategic alternatives.

Negative

  • No current plans disclosed to change control: Filing states no present proposals to effect governance changes, limiting immediate investor impact.
  • Potential group ambiguity: Disclosure that Longitude may be deemed a group member by internal policies could create uncertainty about coordinated holdings despite an express disclaimer.

Insights

TL;DR A ~2% stake purchased for ~$50M signals a meaningful but non-controlling investment; future activity depends on market and strategic review.

The acquisition of 1.54 million shares at $33.00 each represents a sizable capital commitment and increases the Reporting Persons' visibility in CG Oncology. The filing is routine for a large open-market purchase and discloses flexible intent: monitoring the position, potential additional purchases or sales, and possible engagement with management. No explicit plans for board change or control were disclosed. Impact on valuation or governance is limited absent further accumulation or coordinated action.

TL;DR The Schedule 13D flags potential future engagement but currently shows no proposed governance changes.

The filing carefully preserves optionality: the Reporting Persons reserve the right to communicate with management, propose capital allocation changes, or pursue a sale of the company, but state no present plan to effect such actions. The disclosure that Longitude may be deemed a group member under internal policies, combined with an express disclaimer, is notable for governance signaling and potential future coordination considerations. No contractual arrangements or litigation disclosures are reported.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D




Comment for Type of Reporting Person:
Note to Rows 7 and 9: Dr. Liu has been awarded 39,765 options by the Issuer in consideration for his services as a director of the Company, of which 20,341 are currently vested, 5,327 are unvested but will vest within 60 days of the date hereof, and 14,097 of which are unvested and will not have vested within 60 days of the date hereof.


SCHEDULE 13D


Seven Fleet Partners LP
Signature:/s/ Dr. Brian Liu
Name/Title:Dr. Brian Liu, Managing Member of Seven Fleet Advisors, LLC, its Investment Manager
Date:09/18/2025
Seven Fleet Advisors LLC
Signature:/s/ Dr. Brian Liu
Name/Title:Dr. Brian Liu, Managing Member
Date:09/18/2025
Brian Liu
Signature:/s/ Dr. Brian Liu
Name/Title:Dr. Brian Liu
Date:09/18/2025

FAQ

How many CGON shares did Seven Fleet Partners buy and at what price?

Seven Fleet Partners purchased 1,540,819 shares with an aggregate purchase price of approximately $49,999,983; a reported tranche of 1,515,151 shares was bought on September 11, 2025 at $33.00 per share.

What percentage of CG Oncology does Seven Fleet now beneficially own?

The filing reports the Reporting Entities beneficially own 1,515,151 shares, representing 1.9% of the 77,762,732 shares used for the calculation; Dr. Brian Liu is reported at 2% beneficial ownership on his cover page.

Does Seven Fleet plan to change CG Oncology's board or operations?

No. The filing states there are no present plans or proposals to effect changes described in Item 4(a) through (j), though it reserves the right to engage with management or pursue actions in the future.

Did the Reporting Persons disclose any legal proceedings or arrangements?

No. The filing indicates no disclosures of criminal or civil proceedings in the past five years and describes a Joint Filing Agreement among the Reporting Persons as Exhibit 99.1.

What source of funds was used for the purchase?

Seven Fleet Partners states the shares were purchased with working capital, and Seven Fleet Advisors lists AF as its source of funds in the cover page.
CG Oncology, Inc.

NASDAQ:CGON

CGON Rankings

CGON Latest News

CGON Latest SEC Filings

CGON Stock Data

4.52B
73.31M
1.17%
112.6%
13.42%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
IRVINE